Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS after cisplatin + gemcitabine versus cisplatin + gemcitabine in intrahepatic cholangiocarcinoma
2016-003812-10Phase 2Completed
- Sponsor
- Delcath Systems
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of melphalan, cisplatin and gemcitabine in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Delcath Systems. Primary endpoint: Overall survival. Started May 2017; status: completed.
02
Drugs
melphalancisplatingemcitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2016-003812-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003812-10.